Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background/Aims: The utility of Baveno-VII criteria of clinically significant portal hypertension (CSPH) to predict decompensation in compensated advanced chronic liver disease (cACLD) patient needs validation. We aim to validate the performance of CSPH criteria to predict the risk of decompensation in an international real-world cohort of cACLD patients. Methods: cACLD patients were stratified into three categories (CSPH excluded, grey zone, and CSPH). The risks of decompensation across different CSPH categories were estimated using competing risk regression for clustered data, with death and hepatocellular carcinoma as competing events. The performance of “treating definite CSPH” strategy to prevent decompensation using non-selective beta-blocker (NSBB) was compared against other strategies in decision curve analysis. Results: One thousand one hundred fifty-nine cACLD patients (36.8% had CSPH) were included; 7.2% experienced decompensation over a median follow-up of 40 months. Non-invasive assessment of CSPH predicts a 5-fold higher risk of liver decompensation in cACLD patients (subdistribution hazard ratio, 5.5; 95% confidence interval, 4.0–7.4). “Probable CSPH” is suboptimal to predict decompensation risk in cACLD patients. CSPH exclusion criteria reliably exclude cACLD patients at risk of decompensation, regardless of etiology. Among the grey zone, the decompensation risk was negligible among viral-related cACLD, but was substantially higher among the non-viral cACLD group. Decision curve analysis showed that “treating definite CSPH” strategy is superior to “treating all varices” or “treating probable CSPH” strategy to prevent decompensation using NSBB. Conclusions: Non-invasive assessment of CSPH may stratify decompensation risk and the need for NSBB in cACLD patients.
Abstract
Background/Aims: The utility of Baveno-VII criteria of clinically significant portal hypertension (CSPH) to predict decompensation in compensated advanced chronic liver disease (cACLD) patient needs validation. We aim to validate the performance of CSPH criteria to predict the risk of decompensation in an international real-world cohort of cACLD patients. Methods: cACLD patients were stratified into three categories (CSPH excluded, grey zone, and CSPH). The risks of decompensation across different CSPH categories were estimated using competing risk regression for clustered data, with death and hepatocellular carcinoma as competing events. The performance of “treating definite CSPH” strategy to prevent decompensation using non-selective beta-blocker (NSBB) was compared against other strategies in decision curve analysis. Results: One thousand one hundred fifty-nine cACLD patients (36.8% had CSPH) were included; 7.2% experienced decompensation over a median follow-up of 40 months. Non-invasive assessment of CSPH predicts a 5-fold higher risk of liver decompensation in cACLD patients (subdistribution hazard ratio, 5.5; 95% confidence interval, 4.0–7.4). “Probable CSPH” is suboptimal to predict decompensation risk in cACLD patients. CSPH exclusion criteria reliably exclude cACLD patients at risk of decompensation, regardless of etiology. Among the grey zone, the decompensation risk was negligible among viral-related cACLD, but was substantially higher among the non-viral cACLD group. Decision curve analysis showed that “treating definite CSPH” strategy is superior to “treating all varices” or “treating probable CSPH” strategy to prevent decompensation using NSBB. Conclusions: Non-invasive assessment of CSPH may stratify decompensation risk and the need for NSBB in cACLD patients.
참고문헌 (20)
- D'Amico G, "New concepts on the clinical course and stratification of compensated and decompensated cirrhosis", Hepatol Int, 12(Suppl 1), pp.34~43 (2018)
- Ripoll C, "Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis", Gastroenterology, 133, pp.481~488 (2007)
- Villanueva C, "β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension(PREDESCI) : a randomised, double-blind, placebo-controlled, multicentre trial", Lancet, 393, pp.1597~1608 (2019)
- de Franchis R, "BavenoVII-renewing consensus in portalhypertension : report of the Baveno VII consensus workshop : personalized care in portal hypertension", J Hepatol, 76, pp.959~974 (2022)
- Tosetti G, "Decompensation in direct-acting antiviral cured hepatitis C virus compensated patients with clinically significant portal hypertension : too rare to warrant universal Β-blocker therapy", Am J Gastroenterol, 116, pp.1342~1344 (2021)
- Thabut D, "Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy", Gastroenterology, 156, pp.997~1009 (2019)
- European Association for the Study of the Liver, "EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update", J Hepatol, 75, pp.659~689 (2021)
- Pons M, "Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease", Am J Gastroenterol, 116, pp.723~732 (2021)
- Podrug K, "Validation of the new diagnostic criteria for clinically significant portal hypertension by platelets and elastography", Dig Dis Sci, 67, pp.3327~3332 (2021)
- Zhou B, "Competing risks regression for clustered data", Biostatistics, 13, pp.371~383 (2012)
- Vickers AJ, "A simple, step-by-step guide to interpreting decision curve analysis", Diagn Progn Res, 3, pp.18~ (2019)
- Villanueva C, "Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis", J Hepatology, 77, pp.1014~1025 (2022)
- Wong YJ, "Efficacy and safety of sofosbuvir", velpatasvir in a real-world chronic hepatitis C genotype 3 cohort, 2021, pp.36, 1300~1308
- Asesio N, "Baveno VI criteria as a prognostic factor for clinical complications in patients with compensated cirrhosis", Dig Liver Dis, 54, pp.645~653 (2021)
- Abraldes JG, "Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis : the"ANTICIPATE"study", Hepatology, 64, pp.2173~2184 (2016)
- Dajti E, "A combined Baveno VII and spleen stiffness algorithm to improve the non-invasive diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease", Am J Gastroenterol, 117, pp.1825~1833 (2022)
- Sanyal AJ, "Prospective study of outcomes in adults with nonalcoholic fatty liver disease", N Engl J Med, 385, pp.1559~1569 (2021)
- Putera M, "Small esophageal varices in compensated cirrhosis patients : to treat or not to treat?", J Hepatol, 75, pp.491~492 (2021)
- Maurice JB, "Green endoscopy network. Green endoscopy : a call for sustainability in the midst of COVID-19", Lancet Gastroenterol Hepatol, 5, pp.636~638 (2020)
- Yu Jun Wong, "The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients", Clinical and Molecular Hepatology, 27(3), pp.474~485 (2021), 대한간학회[DOI]